Table 1.
Clinical characteristics of participants.
| Items | Control (n=48) | Nicorandil (n=52) | P value |
|---|---|---|---|
| Ages (years) | 64.8±10.5 | 66.4±10.2 | 0.442 |
| Male n (%) | 26 (54.2) | 29 (55.8) | 0.873 |
| Hypertension (n,%) | 32 (66.7) | 33 (63.5) | 0.835 |
| DM (n,%) | 24 (50.0) | 22 (42.3) | 0.547 |
| Hyperlipidemia (n,%) | 41 (85.4) | 40 (76.9) | 0.317 |
| Pharmacotherapy (n,%) | – | – | – |
| Aspirin | 47 (97.9%) | 50 (96.2%) | 0.606 |
| Beta blockers | 22 (45.8) | 24 (46.2) | 0.974 |
| Clopidogrel | 45 (93.8) | 49 (94.2) | 0.919 |
| ACEI/ARB | 38 (79.2) | 34 (65.3) | 0.181 |
DM – diabetes mellitus; ACEI – angiotensin-converting enzyme inhibitors; ARB – angiotensin receptor blocker.